Splenomegaly: Difference between revisions
Line 584: | Line 584: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Associated findings | ||
|- | |- | ||
! rowspan=" | ! rowspan="13" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ||
! rowspan="3" align="center" style="background:#DCDCDC;" |[[Virus|Viral]] | ! rowspan="3" align="center" style="background:#DCDCDC;" |[[Virus|Viral]] | ||
! align="center" style="background:#DCDCDC;" |[[Hepatitis]] | ! align="center" style="background:#DCDCDC;" |[[Hepatitis]] | ||
Line 595: | Line 595: | ||
* Close contact | * Close contact | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 602: | Line 602: | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Lymphadenopathy]] | * [[Lymphadenopathy]] | ||
Line 926: | Line 926: | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
|- | |||
! colspan="2" |Disease | |||
!Etiology | |||
!Demography | |||
!History | |||
!Fever | |||
!Fatigue | |||
!Weight loss | |||
!Abdominal pain | |||
!Bleeding | |||
!BP | |||
!JVP | |||
!Jaundice | |||
!Ascites | |||
!Other | |||
!WBC | |||
!Hb | |||
!Plt | |||
!Iron | |||
!LFT | |||
!PT/PTT | |||
!BUN/Cr | |||
!UA | |||
!Histopathology | |||
!Imaging | |||
!Gold standard | |||
!Associated findings | |||
|- | |- | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Inflammation | ||
Line 1,006: | Line 1,033: | ||
| align="center" style="background:#F5F5F5;" |Nl to ↓ | | align="center" style="background:#F5F5F5;" |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Rash|Skin rash]] | * [[Rash|Skin rash]] | ||
Line 1,043: | Line 1,070: | ||
| align="center" style="background:#F5F5F5;" |Nl to ↓ | | align="center" style="background:#F5F5F5;" |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* [[Pallor]] | * [[Pallor]] | ||
Line 1,103: | Line 1,130: | ||
* Family history | * Family history | ||
| align="center" style="background:#F5F5F5;" | - | | align="center" style="background:#F5F5F5;" | - | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
Line 1,109: | Line 1,136: | ||
| align="center" style="background:#F5F5F5;" |Nl to ↓ | | align="center" style="background:#F5F5F5;" |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" |+ | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
| align="center" style="background:#F5F5F5;" |↓ | | align="center" style="background:#F5F5F5;" |↓ |
Revision as of 23:52, 29 September 2018
WikiDoc Resources for Splenomegaly |
Articles |
---|
Most recent articles on Splenomegaly Most cited articles on Splenomegaly |
Media |
Powerpoint slides on Splenomegaly |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Splenomegaly at Clinical Trials.gov Clinical Trials on Splenomegaly at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Splenomegaly
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Splenomegaly Discussion groups on Splenomegaly Patient Handouts on Splenomegaly Directions to Hospitals Treating Splenomegaly Risk calculators and risk factors for Splenomegaly
|
Healthcare Provider Resources |
Causes & Risk Factors for Splenomegaly |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Gichoya Judy Wawira [2], Moi University School of Medicine
Synonyms and keywords: Spleen enlargement; enlarged spleen; spleen swelling
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Splenomegaly from Other Diseases
Category | Disease | Etiology | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | History | Symptoms | Signs | Lab Findings | Imaging | ||||||||||||||||||||||
Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | CBC | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | |||||||||||
WBC | Hb | Plt | |||||||||||||||||||||||||
Congestive | Cirrhosis[1] | Any, more in elderly | – | + | ↑↓ | + | + | ↓ | Nl | + | + | ↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
|
|
Liver biopsy | |||||
Heart failure[2] | Elderly |
|
– | + | ↑↓ | – | – | ↑ | ↑ | ± | + | ↓ | ↓ | ↑ | Nl | ↑ | ↑ | ↑ | Nl | NA |
|
Echocardiography |
| ||||
Thrombosis of portal, hepatic, or splenic veins[3] | Any | + | + | ↑ | + | + | ↓ | Nl | ± | + | ↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ |
|
NA |
|
Doppler ultrasonography | ||||||
Malignancy | Lymphoma[4] | Any, most common malignant splenic tumor |
|
+ | + | ↓ | + | + | Nl | Nl | + | – | ↓ | ↓ | ↓ | High ferritin | ↑ | ↑ | ↑ | Nl |
|
|
Lymph node biopsy | ||||
Leukemia[5] |
|
Elderly, male>female |
|
+ | + | ↓ | + | + | Nl | Nl | ± | + | ↓ | ↓ | ↓ | High ferritin | ↑ | ↑ | ↑ | Nl |
|
NA | Bone marrow examination + clinical manifestation |
| |||
Polycythemia Vera[6] |
|
Mean age >60 years old |
|
– | + | Nl | + | – | Nl | Nl | – | – |
|
Nl to ↑ | ↑ | Nl to ↑ | High ferritin | Nl | Nl | Nl | Nl |
|
NA | WHO criteria for PV | |||
Disease | Etiology | Demography | History | Fever | Fatigue | Weight loss | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | ||
Multiple myeloma[7] | Any, more in adults |
|
+ | + | ↓ | + | + | Nl | Nl | + | – | ↓ | ↓ | ↓ | High ferritin | Nl | ↑ | ↑ |
|
Bone marrow examination |
| ||||||
Essential thrombocythemia[8] |
|
Mean age >60 years old, female > male |
|
± | + | Nl | + | + | Nl | Nl | – | – | ↑ | ↑ | ↑↑ | Nl | Nl | Nl | Nl | Nl |
|
|
Bone marrow biopsy | ||||
Primary myelofibrosis[9] |
|
Mean age >60 years old, male> female |
|
– | + | Nl | + | + | Nl | Nl | + | – | ↓ | ↓ | ↑/↓ | Low iron | Nl | ↑ | Nl |
|
Bone marrow biopsy |
| |||||
Primary splenic tumors[10] | Rare | ||||||||||||||||||||||||||
Metastatic solid tumors[11] |
|
Any, more in adults |
|
+ | + | ↓ | + | + | ↓ | Nl | ± | ± | ↓ | ↓ | ↓ | Low iron, high ferritin | ↑ | ↑ | ↑ |
|
Biopsy |
| |||||
Category | Disease | Etiology | Demography | History | Fever | Fatigue | Weight | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | |
Infection | Viral | Hepatitis |
|
Any |
|
+ | + | ↓ | + | + | Nl | Nl | + | + |
|
↓ | ↓ | ↓ | Nl | ↑ | ↑ | ↑ | Clinical manifestation + lab tests |
| |||
Infectious mononucleosis |
|
||||||||||||||||||||||||||
Cytomegalovirus | |||||||||||||||||||||||||||
Bacterial | Salmonella | ||||||||||||||||||||||||||
Brucella | |||||||||||||||||||||||||||
Tuberculosis | |||||||||||||||||||||||||||
Parasitic | Malaria | ||||||||||||||||||||||||||
Schistosomiasis | |||||||||||||||||||||||||||
Toxoplasmosis | |||||||||||||||||||||||||||
Kala-azar | Visceral leishmaniasis | ||||||||||||||||||||||||||
Infective endocarditis | |||||||||||||||||||||||||||
Fungal | |||||||||||||||||||||||||||
Disease | Etiology | Demography | History | Fever | Fatigue | Weight loss | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | ||
Inflammation | Sarcoidosis |
|
Autoimmune disease, more in young African American women |
|
+ | + | ↓ | + | + | Nl | Nl | - | - | ↑ | ↓ | ↑ | Nl | Nl | Nl | Nl | Nl | NA |
|
Diagnosis of exclusion |
| ||
Serum sickness | |||||||||||||||||||||||||||
Systemic lupus erythematosus |
|
More in young females |
|
+ | + | ↓ | + | + | Nl to ↓ | Nl | + | + | ↓ | ↓ | ↓ | ↑ | ↑ | ↑ |
|
Clinical findings + laboratory studies |
| ||||||
Felty syndrome |
|
Rare autoimmune disease, more in females 50-70 years old |
|
+ | + | ↓ | + | + | Nl to ↓ | Nl | + | + |
|
↓ | ↓ | ↓ | Nl | Nl | Nl | Nl | Nl |
|
Clinical findings + laboratory studies | ||||
Category | Disease | Etiology | Demography | History | Fever | Fatigue | Weight loss | Abdominal pain | Bleeding | BP | JVP | Jaundice | Ascites | Other | WBC | Hb | Plt | Iron | LFT | PT/PTT | BUN/Cr | UA | Histopathology | Imaging | Gold standard | Associated findings | |
Infiltrative | Gaucher disease[12] |
|
Rare, mostly in children |
|
- | + | ↓ | + | + | Nl to ↓ | Nl | + | + | ↓ | ↓ | ↓ | Nl | Nl | ↑ | ↑ |
|
Clinical findings + laboratory studies | |||||
Niemann-Pick disease | |||||||||||||||||||||||||||
Amyloidosis | |||||||||||||||||||||||||||
Langerhans cell histiocytosis | |||||||||||||||||||||||||||
Hemophagocytic lymphohistiocytosis | |||||||||||||||||||||||||||
Rosai-Dorfman disease | |||||||||||||||||||||||||||
Hematologic (hypersplenic) states | Hemolytic anemia | ||||||||||||||||||||||||||
Sickle cell disease | |||||||||||||||||||||||||||
Granulocyte colony-stimulating factor |
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Treatment
Case Studies
Related Chapters
References
- ↑ Wu Z, Zhou J, Pankaj P, Peng B (December 2012). "Laparoscopic and open splenectomy for splenomegaly secondary to liver cirrhosis: an evaluation of immunity". Surg Endosc. 26 (12): 3557–64. doi:10.1007/s00464-012-2366-5. PMID 22710653.
- ↑ Gedela M, Khan M, Jonsson O (September 2015). "Heart Failure". S D Med. 68 (9): 403–5, 407–9. PMID 26489162.
- ↑ Ferri PM, Ferreira AR, Fagundes ED, Liu SM, Roquete ML, Penna FJ (2012). "Portal vein thrombosis in children and adolescents: 20 years experience of a pediatric hepatology reference center". Arq Gastroenterol. 49 (1): 69–76. PMID 22481689.
- ↑ Ishibashi N, Maebayashi T, Aizawa T, Sakaguchi M, Abe O, Saito T, Tanaka Y (May 2015). "Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma". Hematology. 20 (4): 203–7. doi:10.1179/1607845414Y.0000000192. PMID 25131182.
- ↑ Quest GR, Johnston JB (December 2015). "Clinical features and diagnosis of hairy cell leukemia". Best Pract Res Clin Haematol. 28 (4): 180–92. doi:10.1016/j.beha.2015.10.017. PMID 26614896.
- ↑ Chou YS, Gau JP, Yu YB, Pai JT, Hsiao LT, Liu JH, Hong YC, Liu CY, Yang CF, Chen PM, Chiou TJ, Tzeng CH (March 2013). "Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage". Eur. J. Haematol. 90 (3): 228–36. doi:10.1111/ejh.12064. PMID 23281576.
- ↑ Grieco A, Manna R, Mancini R, Gambassi G (April 1988). "Massive hepatomegaly following splenectomy for myeloid metaplasia". Am. J. Med. 84 (4): 797. PMID 3400674.
- ↑ Tefferi A, Barbui T (February 2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am. J. Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
- ↑ Cervantes F, Martinez-Trillos A (May 2013). "Myelofibrosis: an update on current pharmacotherapy and future directions". Expert Opin Pharmacother. 14 (7): 873–84. doi:10.1517/14656566.2013.783019. PMID 23514013.
- ↑ Adachi K, Ui M, Nojima H, Takada Y, Enatsu K (August 2011). "Isolated splenic peliosis presenting with giant splenomegaly and severe coagulopathy". Am. J. Surg. 202 (2): e17–9. doi:10.1016/j.amjsurg.2010.10.002. PMID 21810495.
- ↑ Huprikar NA, Kurtz MT, Mount CA (October 2013). "Massive splenomegaly and lymphopenia: a unique case of obstructive shock". BMJ Case Rep. 2013. doi:10.1136/bcr-2013-201643. PMC 3822246. PMID 24172780.
- ↑ Ayto R, Hughes DA (2013). "Gaucher disease and myeloma". Crit Rev Oncog. 18 (3): 247–68. PMID 23510067.